Literature DB >> 17681956

The prevalence of inflammation in carotid atherosclerosis: analysis with fluorodeoxyglucose-positron emission tomography.

Nobuhiro Tahara1, Hisashi Kai, Hiroyuki Nakaura, Minori Mizoguchi, Masatoshi Ishibashi, Hayato Kaida, Kenkichi Baba, Naofumi Hayabuchi, Tsutomu Imaizumi.   

Abstract

AIMS: There is increasing evidence that (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging can be useful for non-invasive measurement of atherosclerotic plaque inflammation in humans. However, it is unknown how often atherosclerosis has inflammation in humans. Thus, we examined the prevalence of inflammation in documented carotid atherosclerosis using FDG-PET imaging. METHODS AND
RESULTS: FDG-PET imaging was performed in 100 consecutive patients who underwent carotid artery ultrasonography (CA-US) for screening of carotid atherosclerosis. Carotid atherosclerosis was considered when patients had the plaque score >or=5 and/or the focal thickening of the maximum intima-media complex >or=2 mm (localized plaque) by CA-US. The inflammation of carotid atherosclerosis was quantified by measuring the standardized uptake value (SUV) of FDG of the carotid artery. Inflammation was defined as present if the SUV score was >or=1.60 (>or=1 x standard deviation above the average). FDG-PET imaging revealed inflammation in 12 of 41 (29%) patients having carotid atherosclerosis, whereas in 6 of 59 (10%) patients not having carotid atherosclerosis (P < 0.01). In patients with documented atherosclerosis by CA-US, body mass index, waist circumference, and the number of localized plaques were greater in a subset with inflammation than in a subset without.
CONCLUSION: Inflammation was visualized by FDG-PET imaging in approximately 30% of patients with documented carotid atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17681956     DOI: 10.1093/eurheartj/ehm245

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  35 in total

Review 1.  Rubor, calor, tumor, dolor, functio laesa... or molecular imaging.

Authors:  Giovanni Lucignani
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-12       Impact factor: 9.236

2.  Manual therapy and cervical arterial dysfunction, directions for the future: a clinical perspective.

Authors:  Roger Kerry; Alan J Taylor; Jeanette Mitchell; Chris McCarthy; John Brew
Journal:  J Man Manip Ther       Date:  2008

3.  Capping it off.

Authors:  H William Strauss
Journal:  J Nucl Cardiol       Date:  2009-07-25       Impact factor: 5.952

4.  Vascular FDG uptake: further steps toward clinical acceptance.

Authors:  Frank M Bengel
Journal:  J Nucl Cardiol       Date:  2008 Mar-Apr       Impact factor: 5.952

5.  Gadolinium-Based Contrast Agents for Vessel Wall Magnetic Resonance Imaging (MRI) of Atherosclerosis.

Authors:  Claudia Calcagno; Sarayu Ramachandran; Antoine Millon; Philip M Robson; Venkatesh Mani; Zahi Fayad
Journal:  Curr Cardiovasc Imaging Rep       Date:  2012-10-14

Review 6.  Emerging role of FDG-PET/CT in assessing atherosclerosis in large arteries.

Authors:  Wengen Chen; Gonca G Bural; Drew A Torigian; Daniel J Rader; Abass Alavi
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-11-04       Impact factor: 9.236

Review 7.  Molecular imaging in atherosclerosis.

Authors:  Andor W J M Glaudemans; Riemer H J A Slart; Alessandro Bozzao; Elena Bonanno; Marcello Arca; Rudi A J O Dierckx; Alberto Signore
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-03-20       Impact factor: 9.236

Review 8.  Inflammation in atherosclerosis: from pathophysiology to practice.

Authors:  Peter Libby; Paul M Ridker; Göran K Hansson
Journal:  J Am Coll Cardiol       Date:  2009-12-01       Impact factor: 24.094

Review 9.  The year in molecular imaging.

Authors:  Eric A Osborn; Farouc A Jaffer
Journal:  JACC Cardiovasc Imaging       Date:  2009-01

Review 10.  Pre-clinical and clinical evaluation of nuclear tracers for the molecular imaging of vulnerable atherosclerosis: an overview.

Authors:  L M Riou; A Broisat; J Dimastromatteo; G Pons; D Fagret; C Ghezzi
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.